Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 52
Filtrar
1.
An. bras. dermatol ; 97(2): 193-203, Mar.-Apr. 2022. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1374250

RESUMEN

Abstract Background The effects of chemical straighteners on the scalp and hair shaft are not fully known, although such substances are widely used. Hair straightening became popular in Brazil with the use of formaldehyde and its derivatives, despite the prohibition by the current legislation. Objective To identify changes in hair shaft and scalp caused by the use of chemical straighteners. Methods A search was performed using keywords in three databases from 03/16/2020 to 05/20/2020, with publications between the years 2000 to 2020. After applying the inclusion and exclusion criteria, 33 articles were selected for review. Results In some studies, hair relaxers were associated with eczema, desquamation, pain, burns, and inflammation in the scalp. Hair loss, damage to the shaft, alteration in the color of the hairs and in the composition of their amino acids were observed. Findings are variable across the studies. Study limitations The search was restricted to three databases, in two languages, different study designs were accepted. Conclusions Straightening techniques can have side effects, including scalp inflammation, damage to the shaft, and hair loss. Its long-term effects remain unknown and further studies are necessary.

2.
Surg. cosmet. dermatol. (Impr.) ; 14: e20220074, jan.-dez. 2022.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1369138

RESUMEN

O microagulhamento tem sido tradicionalmente usado para induzir a formação de colágeno. No couro cabeludo, foi observado que estimula a fase anágena e o ciclo capilar, mas faltam estudos que demonstrem as alterações histopatológicas após o procedimento. Relatamos o caso de uma mulher de 37 anos com história de alopecia de padrão feminino há 15 anos, com rarefação difusa proeminente na região fronto-parietal e miniaturização capilar observada à dermatoscopia. A condição permaneceu estável por 7 anos com uso de espironolactona e minoxidil tópico. A paciente foi submetida a três sessões de microagulhamento no couro cabeludo em intervalos mensais. A análise histopatológica foi realizada antes das sessões e um mês após a última sessão. O padrão de alopecia permaneceu o mesmo, sem alterações significativas na contagem de folículos após as intervenções, apesar de discreta melhora clínica e dermatoscópica. Não foram observados tratos fibrosos ou inflamação após o procedimento. A análise histopatológica é importante para avaliar a segurança do microagulhamento do couro cabeludo em curto e longo prazo, para investigar sinais como inflamação e fibrose, bem como para determinar a eficácia deste procedimento no tratamento da alopecia, e estudos com maior número de casos são necessários


Microneedling has traditionally been used to induce collagen formation. Scalp microneedling has been seen to stimulate the capillary cycle and anagen phase, but studies demonstrating histopathological changes after this procedure are lacking. Here we present the case of a 37-year-old woman with a 15-year history of female pattern alopecia, with diffuse hair thinning prominent in the frontoparietal region and hair miniaturization seen in dermoscopy. The patient's condition remained stable for seven years with use of spironolactone and topical minoxidil. The patient underwent three scalp microneedling sessions at monthly intervals. Histopathological analysis was conducted before the sessions and one month after the last session. Despite slight clinical and dermoscopic improvement, the alopecia pattern remained the same, without significant changes in follicle count after the interventions. Neither inflammation nor fibrous tracts were observed after the procedure. The histopathological analysis is essential to assess the safety of scalp microneedling in the short and long term, investigate signs such as inflammation and fibrosis, and determine the effectiveness of this procedure in treating alopecia. Studies with a more significant number of cases are necessary

3.
An. bras. dermatol ; 95(supl.1): 39-52, Nov.-Dec. 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1152777

RESUMEN

Abstract Background: Alopecia areata is a highly frequent disease with an impact on quality of life and several treatment options with little clinical confirmatory evidence. Objective: To disseminate the recommendations of Brazilian dermatologists with expertise in the treatment of alopecia areata. Methods: Eight specialists with expertise in alopecia areata from different university centers were appointed by the Brazilian Society of Dermatology to reach a consensus on its treatment. Based on the adapted DELPHI methodology, the relevant elements were considered; then, an analysis of recent literature was carried out and the consensus was written down. Consensus on the management of alopecia areata was defined with the approval of at least 70% of the panel. Results/Conclusions: Intralesional injectable corticotherapy was considered the first option for localized disease in adults. In extensive cases with signs of activity, systemic corticosteroid therapy should be considered and can be used together with immunosuppressants (corticosteroid-sparing agents). The use of an immunosensitizer (diphencyprone) is an option for stable long-term cases. Evaluation of side effects is as important as the rate of hair regrowth.


Asunto(s)
Humanos , Adulto , Dermatología , Alopecia Areata/tratamiento farmacológico , Calidad de Vida , Brasil , Consenso
7.
Surg. cosmet. dermatol. (Impr.) ; 9(4): 331-333, out.-dez. 2017. ilus.
Artículo en Inglés, Portugués | LILACS | ID: biblio-880523

RESUMEN

A sarcoidose é doença granulomatosa não infecciosa de etiologia desconhecida, em que fatores ambientais, infecciosos, imunológicos e genéticos parecem estar relacionados. Manifestações clínicas podem ocorrer em qualquer órgão, mas há predomínio em pulmão e linfonodos intratorácicos. O envolvimento cutâneo da doença ocorre em cerca de 25% dos casos, sendo o procedimento de preenchimento cutâneo um potencial desencadeante. Relata-se caso de uma paciente que apresentou lesões granulomatosas na face após preenchimento cutâneo com ácido hialurônico. Na investigação das lesões cutâneas, a paciente apresentou critérios diagnósticos de sarcoidose com extenso acometimento pulmonar.


Sarcoidosis is a non-infectious granulomatous disease of unknown etiology in which environmental, infectious, immunological, and genetic factors appear to be correlated. Clinical manifestations can occur in any organ, however there is predominance in the lungs and in intrathoracic lymph nodes. The cutaneous involvement of the disease occurs in roughly 25% of cases, with cutaneous filling procedures figuring as a potential trigger. The authors of the present article report a case of a patient who had granulomatous lesions on the face following cutaneous filling with hyaluronic acid. In the investigation of cutaneous lesions, the patient presented diagnostic criteria for sarcoidosis, with extensive pulmonary involvement.

9.
An. bras. dermatol ; 92(5,supl.1): 79-81, 2017. graf
Artículo en Inglés | LILACS | ID: biblio-887090

RESUMEN

Abstract Frontal fibrosing alopecia is a variant of lichen planopilaris with marginal progressive hair loss on the scalp, eyebrows and axillae. We report a case of frontal fibrosing alopecia and lichen planus pigmentosus in a postmenopausal woman, that started with alopecia on the eyebrows and then on the frontoparietal region, with periocular and cervical hyperpigmentation of difficult management. The condition was controlled with systemic corticosteroid therapy and finasteride. Lichen planus pigmentosus is an uncommon variant of lichen planus frequently associated with frontal fibrosing alopecia in darker phototipes. It should be considered in patients affected by scarring alopecia with a pattern of lichen planopilaris and areas of skin hyperpigmentation revealing perifollicular hyperpigmentation refractory to multiple treatments. This case illustrates diagnostic and therapeutic challenge in face of scarring alopecia and perifollicular hyperpigmentation.


Asunto(s)
Humanos , Femenino , Anciano , Hiperpigmentación/patología , Hiperpigmentación/tratamiento farmacológico , Alopecia/patología , Alopecia/tratamiento farmacológico , Liquen Plano/tratamiento farmacológico , Piel/patología , Biopsia , Resultado del Tratamiento , Corticoesteroides/uso terapéutico , Posmenopausia , Finasterida/uso terapéutico , Dermoscopía , Frente/patología , Liquen Plano/patología
11.
Surg. cosmet. dermatol. (Impr.) ; 8(2): 179-181, Abr.-Jun. 2016. ilus
Artículo en Inglés, Portugués | LILACS | ID: biblio-874913

RESUMEN

O ácido hialurônico é o preenchedor atualmente mais utilizado na dermatologia devido ao baixo risco de efeitos colaterais. O objetivo deste trabalho é relatar um caso de reação granulomatosa após preenchimento com dois tipos de ácido hialurônico, na região perioral e no sulco nasogeniano. A paciente, portadora de artrite reumatoide em tratamento com leflunomide, apresentou início dos sintomas 30 meses após o preenchimento. Doenças autoimunes podem facilitar a ocorrência de complicações e devem ser observadas com cuidado antes do preenchimento com ácido hialurônico. Como já relatado com uso de interferon e omalizumab, a reação granulomatosa por preenchedores pode ocorrer após o uso de leflunomide.


Hyaluronic acid is the currently most used filler in dermatology due to its low risk of adverse events. The objective of this study is to report a case of granulomatous reaction after filling with two types of hyaluronic acid, in the perioral region and in the nasolabial folds. A female patient with rheumatoid arthritis treated with leflunomide presented onset of symptoms 30 months after filling. Autoimmune diseases may facilitate the occurrence of complications and should be followed carefully before filling with hyaluronic acid. As already reported with the use of interferon and omalizumab, granulomatous reaction to fillers may occur after use of leflunomide.

12.
An. bras. dermatol ; 90(6): 814-821, Nov.-Dec. 2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-769513

RESUMEN

Abstract: BACKGROUND: Permanent alopecia after bone marrow transplantation is rare, but more and more cases have been described, typically involving high doses of chemotherapeutic agents used in the conditioning regimen for the transplant. Busulfan, classically described in cases of irreversible alopecia, remains associated in recent cases. The pathogenesis involved in hair loss is not clear and there are few studies available. In addition to chemotherapeutic agents, another factor that has been implicated as a cause is chronic graft-versus-host disease. However, there are no histopathological criteria for defining this diagnosis yet. OBJECTIVE: the study aims to evaluate clinical and histological aspects in cases of permanent alopecia after bone marrow transplantation, identifying features of permanent alopecia induced by myeloablative chemotherapy and alopecia as a manifestation of chronic graft-versus-host disease. METHODS: data were collected from medical records of 7 patients, with description of the clinical features and review of slides and paraffin blocks of biopsies. RESULTS: Two distinct histological patterns were found: one similar to androgenetic alopecia, non-scarring pattern, and other similar to lichen planopilaris, scarring alopecia. CONCLUSION: The first pattern corroborates the literature cases of permanent alopecia induced by chemotherapeutic agents, and the second is compatible with manifestation of chronic graft-versus-host disease on scalp, that has never been described yet. The results contribute to the elucidation of the factors involved in these cases, including the development of therapeutic methods.


Asunto(s)
Adulto , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Alopecia/inducido químicamente , Alopecia/patología , Trasplante de Médula Ósea/efectos adversos , Busulfano/efectos adversos , Enfermedad Injerto contra Huésped/complicaciones , Agonistas Mieloablativos/efectos adversos , Biopsia , Enfermedad Crónica , Folículo Piloso/patología , Estudios Retrospectivos , Cuero Cabelludo/patología , Factores de Tiempo
13.
An. bras. dermatol ; 90(6,supl.1): 1-16, Nov.-Dec. 2015. tab, graf
Artículo en Inglés | LILACS | ID: lil-781351

RESUMEN

Abstract: BACKGROUND: The current options for the treatment of acne vulgaris present many mechanisms of action. For several times, dermatologists try topical agents combinations, looking for better results. OBJECTIVES: To evaluate the efficacy, tolerability and safety of a topical, fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel for the treatment of acne vulgaris in the Brazilian population. METHODS: This is a multicenter, open-label and interventionist study. Patients applied 1.0 g of the fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel on the face, once daily at bedtime, during 12 weeks. Lesions were counted in all of the appointments, and the degree of acne severity, overall improvement, tolerability and safety were evaluated in each visit. RESULTS: From 79 recruited patients, 73 concluded the study. There was significant, fast and progressive reduction of non-inflammatory, inflammatory and total number of lesions. At the end of the study, 75.3% of patients had a reduction of >50% in non-inflammatory lesions, 69.9% in inflammatory lesions and 78.1% in total number of lesions. Of the 73 patients, 71.2% had good to excellent response and 87.6% had satisfactory to good response. In the first week of treatment, erythema, burning, scaling and dryness of the skin were frequent complaints, but, from second week on, these signals and symptoms have reduced. CONCLUSION: The fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5% gel is effective, safe, well tolerated and apparently improves patient compliance with the treatment.


Asunto(s)
Masculino , Femenino , Niño , Adolescente , Adulto , Adulto Joven , Acné Vulgar/tratamiento farmacológico , Fármacos Dermatológicos/administración & dosificación , Combinación Adapaleno y Peróxido de Benzoílo/administración & dosificación , Factores de Tiempo , Índice de Severidad de la Enfermedad , Brasil , Antiinflamatorios no Esteroideos/administración & dosificación , Reproducibilidad de los Resultados , Resultado del Tratamiento , Satisfacción del Paciente , Acné Vulgar/patología , Estadísticas no Paramétricas , Relación Dosis-Respuesta a Droga
14.
An. bras. dermatol ; 90(5): 654-659, graf
Artículo en Inglés | LILACS | ID: lil-764419

RESUMEN

AbstractBACKGROUND:Leprosy is an infectious disease that may lead to irreversible nerve damage, compromising patient's quality of life and leading to loss of working years.OBJECTIVES:To evaluate the epidemiological profile of patients followed at a University Hospital.MATERIALS AND METHODS: This is a retrospective observational study, based on a review of medical records. We studied the clinical and epidemiological features of patients with leprosy monitored at the Hospital de Clínicas of the Federal University of Paraná between January 2005 and January 2010.RESULTS:The mean age was 47.51, while 35.94% of patients were aged 41-60. The male:female rate was 1.8:1. The most prevalent occupations were: retired, students or rural workers. Patients came mainly from Curitiba or nearby areas, but there were also patients from the countryside. The mean diagnostic delay was 24.57 months. Multibacillary forms prevailed, with the lepromatous variety being the most common, closely followed by the borderline type. Neural enlargement was found in more than 50% of the patients and 48.44% of them developed reactional states. Hemolysis was the most commonly detected drug side effect. Initial functional evaluation was possible in 70% of patients, 55% of whom had disabilities upon diagnosis. The most prevalent associated disease was hypertension.CONCLUSIONS:This study showed an important diagnostic delay and a high rate of sequelae in this specific population. Brazil is one of the few remaining countries that has not yet eradicated leprosy and it is important to improve health policies in order to prevent sequelae and achieve eradication.


Asunto(s)
Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Lepra/epidemiología , Distribución por Edad , Brasil/epidemiología , Diagnóstico Tardío , Evaluación de la Discapacidad , Hospitales Universitarios/estadística & datos numéricos , Lepra/diagnóstico , Lepra/terapia , Registros Médicos/estadística & datos numéricos , Prevalencia , Estudios Retrospectivos , Distribución por Sexo , Resultado del Tratamiento
15.
An. bras. dermatol ; 90(5): 666-670, tab, graf
Artículo en Inglés | LILACS | ID: lil-764422

RESUMEN

AbstractBACKGROUND:Lichen planopilaris is a frequent presentation of primary cicatricial alopecia. Scalp distribution characterizes the main clinical presentations: classic lichen planopilaris, frontal fibrosing alopecia and Graham-Little Piccardi-Lassueur Syndrome (GLPLS).OBJECTIVE:Description of the clinical, dermoscopic and histopathological findings of Lichen planopilaris in public and private practices.METHOD:A retrospective observational study was performed by reviewing medical records of patients with lichen planopilaris.RESULTS:Eighty patients were included, 73 (91,25%) were female. Prototype II was seen in 53 (66,25%) patients. Classic lichen planopilaris was seen in 62,5% of the cases. Frontal fibrosing alopecia was seen in 31% of the patients and only one patient presented Graham-Little Piccardi-Lassueur Syndrome (GLPLS). Scalp lesions were scattered throughout the scalp in 47 (58,75%) of the patients, while 24 (30%) presented mainly central scalp lesions, 29 (36,25%) presented marginal lesions and only 4 (5%) patents had vertex lesions.CONCLUSIONS:Clinical presentation of Lichen planopilaris varies. To recognize the heterogeneity of the clinical appearance in lichen planopilaris is important for differential diagnosis.


Asunto(s)
Femenino , Humanos , Masculino , Alopecia/epidemiología , Liquen Plano/epidemiología , Alopecia/patología , Brasil/epidemiología , Dermoscopía , Queratosis/epidemiología , Queratosis/patología , Liquen Plano/patología , Registros Médicos , Estudios Retrospectivos , Cuero Cabelludo/patología
17.
An. bras. dermatol ; 90(3,supl.1): 59-61, May-June 2015. tab, ilus
Artículo en Inglés | LILACS | ID: lil-755774

RESUMEN

Abstract

Dermatosis neglecta is the name of a skin condition characterized by papules and polygonal plaques, which are sometimes warty, brownish and hyperpigmented, adherent and symmetric, though removable with ethyl or isopropyl alcohol. It occurs due to inadequate skin cleansing causing accumulation of sebum, sweat, keratin and impurities. Its occurrence, though little reported, is frequent. The main differential diagnosis is the Terra fi rma-forme dermatosis. The treatment is simple, with exfoliation, moisturizing and even rubbing of alcohol. Causes of negligence on the patient’s side, which can range from hygiene carelessness to psychiatric disorders, local hypersensitivity, limbs negligence or motor paralysis, should be investigated. We illustrate the case of dermatosis neglecta in a 45-years old patient admitted with pulmonary sepsis.

.


Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Piel/patología , Enfermedades de la Piel/patología , Enfermedades de la Piel/etiología , Hiperpigmentación/patología , Cuidados de la Piel , Dermoscopía , Diagnóstico Diferencial
18.
An. bras. dermatol ; 89(6): 878-884, Nov-Dec/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-727648

RESUMEN

BACKGROUND: Masseter hypertrophy has been treated with botulinum toxin injections because of esthetic complaints especially in Asians. OBJECTIVES: The goal of the present study was to evaluate the efficacy of abobotulin toxin use in masseter hipertrophy treatment in Brazilians. METHODS: Ten Brazilian female patients with masseter hypertrophy were subjected to injections of 90U of abobotulinum toxin A applied on each side respecting the safety zone stabilished in literature and were followed up for 24 weeks. RESULTS: When analyzing the coefficients between measures of middle and lower third of the face obtained from standardized photographs, an increase was observed, with statistical significance at 2 weeks (p=0.005) and 12 weeks (p=0.001). The progression of lower third reduction was 3.94%, 5.26%, 11.99%, and 5.47% (2, 4, 12, and 24 weeks respectively). All patients showed improvement in bruxism after treatment. Observed adverse effects were masticatory fatigue, smile limitation, and smile asymmetry. CONCLUSION: The use of abobotulinum toxin A for masseter hypertrophy is effective in Brazilians and reached its maximum effect of facial thinning at 12 weeks. Smile limitation had a higher incidence compared to that reported in the literature and may result from risorius muscle blockage caused by toxin dissemination. Despite its side effects, 80% of the patients would like to repeat the treatment. .


Asunto(s)
Adulto , Femenino , Humanos , Toxinas Botulínicas Tipo A/uso terapéutico , Hipertrofia/tratamiento farmacológico , Músculo Masetero/anomalías , Músculo Masetero/efectos de los fármacos , Fármacos Neuromusculares/uso terapéutico , Brasil/etnología , Cara , Inyecciones Intramusculares , Sonrisa/fisiología , Factores de Tiempo , Resultado del Tratamiento
19.
An. bras. dermatol ; 89(5): 729-734, Sep-Oct/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-720783

RESUMEN

BACKGROUND: Alopecia areata is a chronic disorder of the hair follicles and nails, of unknown etiology, with clear autoimmune components and genetic factors. Several therapeutic options have been suggested; however, no treatment is able to modify the disease course. Methotrexate is an immunosuppressant used in various dermatoses and recently introduced as a therapeutic option for alopecia areata. OBJECTIVES: To evaluate the efficacy and safety of methotrexate in alopecia areata. METHODS: In a retrospective, non-controlled study, we evaluated 31 patients with alopecia areata in current or prior treatment with methotrexate to assess the therapeutic response according to sex, age, pattern of alopecia areata, disease duration, cumulative dose of methotrexate, use of systemic corticosteroids or other treatments, and drug safety. RESULTS: Regrowth greater than 50% was observed in 67.7% of patients, with the best responses observed in those with <5 years of disease progression (79%), age over 40 years (73.3%), male patients (72.8%), cumulative dose of methotrexate 1000-1500 mg, and multifocal alopecia areata (93%). Among patients receiving systemic corticosteroids in combination with methotrexate, 77.3% had greater than 50% regrowth, compared with 44.4% in those who used methotrexate alone. The therapeutic dose ranged from 10-25 mg/week. No patient had serious adverse effects. Relapse was observed in 33.3% of patients with more than 50% regrowth. CONCLUSION: Methotrexate appears to be a promising and safe medication for the treatment of severe alopecia areata when used alone or in combination with corticosteroids. .


Asunto(s)
Adolescente , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Alopecia Areata/tratamiento farmacológico , Inmunosupresores/administración & dosificación , Metotrexato/administración & dosificación , Factores de Edad , Corticoesteroides/uso terapéutico , Quimioterapia Combinada , Reproducibilidad de los Resultados , Estudios Retrospectivos , Factores de Riesgo , Factores Sexuales , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA